BACKGROUND: Single-nucleotide polymorphisms (SNPs) in toll-like receptors (TLR) 1, 2, and 6 impair cell signaling in response to spirochetal lipoproteins. We investigated whether common SNPs in TLR1, TLR2, or TLR6 were associated with laboratory- or clinically-defined neurosyphilis. METHODS: Polymorphisms in the genes for TLR1 (a T→G mutation at position 1805), TLR2 (a G→A mutation at position 2258), and TLR6 (a C→T mutation at position 745) were sought in 456 white patients with syphilis. Laboratory-defined neurosyphilis included a reactive cerebrospinal fluid (CSF)-Venereal Disease Research Laboratory (VDRL) test. Clinically-defined neurosyphilis included new vision or hearing loss. Controls had CSF white blood cells of 5/μL or less, nonreactive CSF-Venereal Disease Research Laboratory, and no vision or hearing loss. RESULTS: Overall, 26.2% of patients had laboratory-defined and 36.2% had clinically-defined neurosyphilis. Compared with controls, patients with any of the 3 SNPs were more likely to have laboratory-defined neurosyphilis. Those with TLR2 or TLR6 SNPs were more likely to have clinically-defined neurosyphilis. These associations were independent of serum rapid plasma reagin titer. CONCLUSIONS: A common TLR1 polymorphism is associated with an increased risk of laboratory-defined neurosyphilis, and common TLR2 and TLR6 polymorphisms are associated with an increased risk of both laboratory- and clinically-defined neurosyphilis. These data suggest that host factors impact the natural history of syphilis.
BACKGROUND: Single-nucleotide polymorphisms (SNPs) in toll-like receptors (TLR) 1, 2, and 6 impair cell signaling in response to spirochetal lipoproteins. We investigated whether common SNPs in TLR1, TLR2, or TLR6 were associated with laboratory- or clinically-defined neurosyphilis. METHODS: Polymorphisms in the genes for TLR1 (a T→G mutation at position 1805), TLR2 (a G→A mutation at position 2258), and TLR6 (a C→T mutation at position 745) were sought in 456 white patients with syphilis. Laboratory-defined neurosyphilis included a reactive cerebrospinal fluid (CSF)-Venereal Disease Research Laboratory (VDRL) test. Clinically-defined neurosyphilis included new vision or hearing loss. Controls had CSF white blood cells of 5/μL or less, nonreactive CSF-Venereal Disease Research Laboratory, and no vision or hearing loss. RESULTS: Overall, 26.2% of patients had laboratory-defined and 36.2% had clinically-defined neurosyphilis. Compared with controls, patients with any of the 3 SNPs were more likely to have laboratory-defined neurosyphilis. Those with TLR2 or TLR6 SNPs were more likely to have clinically-defined neurosyphilis. These associations were independent of serum rapid plasma reagin titer. CONCLUSIONS: A common TLR1 polymorphism is associated with an increased risk of laboratory-defined neurosyphilis, and common TLR2 and TLR6 polymorphisms are associated with an increased risk of both laboratory- and clinically-defined neurosyphilis. These data suggest that host factors impact the natural history of syphilis.
Authors: Péter Nagyoszi; Imola Wilhelm; Attila E Farkas; Csilla Fazakas; Ngo Thi Khue Dung; János Haskó; István A Krizbai Journal: Neurochem Int Date: 2010-07-14 Impact factor: 3.921
Authors: Christina M Marra; Sharon K Sahi; Lauren C Tantalo; Charmie Godornes; Tara Reid; Frieda Behets; Anne Rompalo; Jeffrey D Klausner; Yue Ping Yin; Fiona Mulcahy; Matthew R Golden; Arturo Centurion-Lara; Sheila A Lukehart Journal: J Infect Dis Date: 2010-11-01 Impact factor: 5.226
Authors: Marije Oosting; Hadewych Ter Hofstede; Patrick Sturm; Gosse J Adema; Bart-Jan Kullberg; Jos W M van der Meer; Mihai G Netea; Leo A B Joosten Journal: PLoS One Date: 2011-10-05 Impact factor: 3.240
Authors: Adriana R Cruz; Lady G Ramirez; Ana V Zuluaga; Allan Pillay; Christine Abreu; Carlos A Valencia; Carson La Vake; Jorge L Cervantes; Star Dunham-Ems; Richard Cartun; Domenico Mavilio; Justin D Radolf; Juan C Salazar Journal: PLoS Negl Trop Dis Date: 2012-07-17
Authors: Christina M Marra; Lauren C Tantalo; Sharon K Sahi; Shelia B Dunaway; Sheila A Lukehart Journal: J Infect Dis Date: 2015-12-09 Impact factor: 5.226
Authors: Linda Grillová; Jana Musilová; Klára Janečková; Petra Pospíšilová; Ivana Kuklová; Vladana Woznicová; Hana Zákoucká; David Šmajs Journal: Infect Immun Date: 2020-12-15 Impact factor: 3.441
Authors: Emily L Ho; Clare L Maxwell; Shelia B Dunaway; Sharon K Sahi; Lauren C Tantalo; Sheila A Lukehart; Christina M Marra Journal: Clin Infect Dis Date: 2017-09-15 Impact factor: 9.079
Authors: Gustavo Henrique Pereira Boog; João Vitor Ziroldo Lopes; João Vitor Mahler; Marina Solti; Lucas Tokio Kawahara; Andre Kakinoki Teng; João Victor Taba Munhoz; Anna S Levin Journal: BMC Infect Dis Date: 2021-06-14 Impact factor: 3.090